News
For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...
Sarepta Therapeutics (SRPT) stock is downgraded at Bank of America based on safety concerns related to the company's Elevidys gene therapy for Duchenne. Read more here.
There are about $10.5 billion of biotech convertibles outstanding, roughly 3% of the $305 billion market, according to BofA Securities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results